PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity
Citations Over TimeTop 12% of 2016 papers
Abstract
Osteosarcoma (OS) is a highly aggressive pediatric bone cancer in which most tumor cells remain immature and fail to differentiate into bone-forming osteoblasts. However, OS cells readily respond to adipogenic stimuli suggesting they retain mesenchymal stem cell-like properties. Here we demonstrate that nuclear receptor PPARγ agonists such as the anti-diabetic, thiazolidinedione (TZD) drugs induce growth arrest and cause adipogenic differentiation in human, mouse and canine OS cells as well as in tumors in mice. Gene expression analysis reveals that TZDs induce lipid metabolism pathways while suppressing targets of the Hippo-YAP pathway, Wnt signaling and cancer-related proliferation pathways. Significantly, TZD action appears to be restricted to the high Sox2 expressing cancer stem cell population and is dependent on PPARγ expression. TZDs also affect growth and cell fate by causing the cytoplasmic sequestration of the transcription factors SOX2 and YAP that are required for tumorigenicity. Finally, we identify a TZD-regulated gene signature based on Wnt/Hippo target genes and PPARγ that predicts patient outcomes. Together, this work highlights a novel connection between PPARγ agonist in inducing adipogenesis and mimicking the tumor suppressive hippo pathway. It also illustrates the potential of drug repurposing for TZD-based differentiation therapy for osteosarcoma.
Related Papers
- → Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck(2008)167 cited
- → CD44+CD133+population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma(2010)81 cited
- → Characterization of CD44-positive Cancer Stem-like Cells in COLO 201 Cells(2019)16 cited
- → The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells(2023)3 cited
- → [Carcinogenicity study of CD133(+)CD44(+) laryngeal cancer stem cells and identification of related microRNAs].(2019)1 cited